BIOGEN INC (BIIB) Stock Fundamental Analysis

NASDAQ:BIIB • US09062X1037

192.03 USD
-0.05 (-0.03%)
At close: Feb 20, 2026
192.03 USD
0 (0%)
After Hours: 2/20/2026, 8:18:47 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to BIIB. BIIB was compared to 521 industry peers in the Biotechnology industry. BIIB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BIIB is valued quite cheap, but it does not seem to be growing. These ratings would make BIIB suitable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • BIIB had positive earnings in the past year.
  • BIIB had a positive operating cash flow in the past year.
  • BIIB had positive earnings in each of the past 5 years.
  • In the past 5 years BIIB always reported a positive cash flow from operatings.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • BIIB has a better Return On Assets (4.39%) than 90.59% of its industry peers.
  • BIIB's Return On Equity of 7.08% is amongst the best of the industry. BIIB outperforms 90.98% of its industry peers.
  • BIIB's Return On Invested Capital of 8.93% is amongst the best of the industry. BIIB outperforms 94.05% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 18.64%.
  • The last Return On Invested Capital (8.93%) for BIIB is above the 3 year average (8.93%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 13.07%, BIIB belongs to the top of the industry, outperforming 91.94% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BIIB has declined.
  • BIIB has a Operating Margin of 27.94%. This is amongst the best in the industry. BIIB outperforms 96.74% of its industry peers.
  • BIIB's Operating Margin has declined in the last couple of years.
  • BIIB has a Gross Margin of 75.69%. This is amongst the best in the industry. BIIB outperforms 84.26% of its industry peers.
  • BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
  • Compared to 1 year ago, BIIB has more shares outstanding
  • The number of shares outstanding for BIIB has been reduced compared to 5 years ago.
  • BIIB has a better debt/assets ratio than last year.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.36 indicates that BIIB is not in any danger for bankruptcy at the moment.
  • BIIB's Altman-Z score of 3.36 is fine compared to the rest of the industry. BIIB outperforms 68.52% of its industry peers.
  • BIIB has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as BIIB would need 3.11 years to pay back of all of its debts.
  • The Debt to FCF ratio of BIIB (3.11) is better than 92.71% of its industry peers.
  • A Debt/Equity ratio of 0.34 indicates that BIIB is not too dependend on debt financing.
  • BIIB has a worse Debt to Equity ratio (0.34) than 68.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.36
ROIC/WACC1.09
WACC8.22%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • BIIB has a Current Ratio of 2.68. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • BIIB's Current ratio of 2.68 is on the low side compared to the rest of the industry. BIIB is outperformed by 69.10% of its industry peers.
  • BIIB has a Quick Ratio of 2.03. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • BIIB's Quick ratio of 2.03 is on the low side compared to the rest of the industry. BIIB is outperformed by 74.28% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • BIIB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
  • BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
  • Looking at the last year, BIIB shows a small growth in Revenue. The Revenue has grown by 2.22% in the last year.
  • Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -5.96% on average per year.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.54% on average over the next years.
  • Based on estimates for the next years, BIIB will show a decrease in Revenue. The Revenue will decrease by -0.42% on average per year.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.56, the valuation of BIIB can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.50% of the companies listed in the same industry.
  • BIIB is valuated cheaply when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 12.62, which indicates a correct valuation of BIIB.
  • Based on the Price/Forward Earnings ratio, BIIB is valued cheaply inside the industry as 97.31% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of BIIB to the average of the S&P500 Index (28.02), we can say BIIB is valued rather cheaply.
Industry RankSector Rank
PE 12.56
Fwd PE 12.62
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 97.89% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 97.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.96
EV/EBITDA 8.42
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

NASDAQ:BIIB (2/20/2026, 8:18:47 PM)

After market: 192.03 0 (0%)

192.03

-0.05 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner Change3.93%
Ins Owners0.15%
Ins Owner Change7.98%
Market Cap28.18B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.33
Price Target195.32 (1.71%)
Short Float %3.2%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)1.07%
PT rev (3m)8.84%
EPS NQ rev (1m)-13.94%
EPS NQ rev (3m)-13.38%
EPS NY rev (1m)-1.51%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-1.51%
Revenue NQ rev (3m)-0.95%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.7%
Valuation
Industry RankSector Rank
PE 12.56
Fwd PE 12.62
P/S 2.85
P/FCF 13.96
P/OCF 12.78
P/B 1.54
P/tB 10.89
EV/EBITDA 8.42
EPS(TTM)15.29
EY7.96%
EPS(NY)15.21
Fwd EY7.92%
FCF(TTM)13.76
FCFY7.16%
OCF(TTM)15.02
OCFY7.82%
SpS67.39
BVpS124.4
TBVpS17.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number206.87
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.36
F-Score4
WACC8.22%
ROIC/WACC1.09
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year11.48%
EBIT Next 3Y4.64%
EBIT Next 5Y1.32%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / BIIB FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 7 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 7 / 10.